ZOLINZA Drug Patent Profile
✉ Email this page to a colleague
When do Zolinza patents expire, and what generic alternatives are available?
Zolinza is a drug marketed by Msd Sub Merck and is included in one NDA. There are five patents protecting this drug.
This drug has one hundred and thirty-one patent family members in thirty-five countries.
The generic ingredient in ZOLINZA is vorinostat. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vorinostat profile page.
DrugPatentWatch® Generic Entry Outlook for Zolinza
Zolinza was eligible for patent challenges on October 6, 2010.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 11, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZOLINZA?
- What are the global sales for ZOLINZA?
- What is Average Wholesale Price for ZOLINZA?
Summary for ZOLINZA
| International Patents: | 131 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 136 |
| Clinical Trials: | 161 |
| Patent Applications: | 4,651 |
| Drug Prices: | Drug price information for ZOLINZA |
| What excipients (inactive ingredients) are in ZOLINZA? | ZOLINZA excipients list |
| DailyMed Link: | ZOLINZA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZOLINZA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ZOLINZA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| OHSU Knight Cancer Institute | Phase 1 |
| Prospect Creek Foundation | Phase 1 |
| Oregon Health and Science University | Phase 1 |
Pharmacology for ZOLINZA
| Drug Class | Histone Deacetylase Inhibitor |
| Mechanism of Action | Histone Deacetylase Inhibitors |
US Patents and Regulatory Information for ZOLINZA
ZOLINZA is protected by five US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZOLINZA is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ZOLINZA
Methods of treating cancer with HDAC inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
Polymorphs of suberoylanilide hydroxamic acid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Polymorphs of suberoylanilide hydroxamic acid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
Formulations of suberoylanilide hydroxamic acid and methods for producing the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Formulations of suberoylanilide hydroxamic acid and methods for producing same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZOLINZA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZOLINZA
See the table below for patents covering ZOLINZA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Portugal | 1663194 | ⤷ Sign Up | |
| South Africa | 200601757 | Methods of inducing terminal differentiation | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2006127321 | ⤷ Sign Up | |
| Israel | 173846 | ⤷ Sign Up | |
| Australia | 2009201668 | Methods of Treating Cancer with HDAC Inhibitors | ⤷ Sign Up |
| European Patent Office | 1663194 | Utilisation de SAHA pour traiter le mésotheliome (Use of SAHA for treating mesothelioma) | ⤷ Sign Up |
| Brazil | 0308250 | Métodos de indução de diferenciação terminal | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
